What You Should Know:
- NVIDIA announced widespread adoption of its open-source BioNeMo™ Framework by pharmaceutical companies, techbio innovators, and AI researchers to accelerate drug discovery and molecule design.
- The framework provides a powerful suite of tools for scaling AI models in biomolecular research, bringing supercomputing capabilities to the forefront of drug development.
Accelerating Drug Discovery with AI
The BioNeMo Framework addresses the growing need
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
How Temporal Artery Thermometry Improves Patient Safety Through Accurate Temperature Monitoring
Accurate and frequent temperature monitoring is paramount when it comes to ensuring favorable patient outcomes in the medical community. When a patient is admitted to the hospital, identifying illness or infection quickly has a profound impact on allowing for prompt treatment with antibiotics and can also be critical in the early identification of serious, life-threatening conditions like sepsis.
With the proliferation of less accurate temperature monitoring options during the
Read More
Navigating the Complexities of Preclinical and Clinical Trials
The development of new drugs or medical interventions is a meticulous process involving various stages to ensure safety, efficacy, and regulatory compliance. Central to this journey are the preclinical and clinical trial phases, which are vital for transitioning from laboratory research to clinical application. Let us take a look at the whole process – step by step.
Preclinical Studies: Laying the Groundwork
The preclinical phase involves extensive in vitro (test tube or cell culture) and
Read More
Q/A: Funding Landscape: IPO or Buyout for Life Science Companies?
Life science companies, particularly those heavily invested in research and development, often face critical funding decisions. Should they pursue an initial public offering (IPO) to fuel their growth, or is a strategic buyout from a larger company a more suitable path?
In this exclusive interview, Taylor Wirth, a partner at Barnes & Thornburg, offers his insights on evaluating market conditions, assessing company readiness, and weighing the pros and cons of each funding option. He
Read More
NVentures Invests in Genesis Therapeutics’ AI Platform for Drug Development
What You Should Know:
- Genesis Therapeutics, a company pioneering artificial intelligence (AI) technologies to create breakthrough medicines for patients, announced today a further equity investment from NVentures, NVIDIA’s venture capital arm.
- This investment is in addition to NVentures’ participation in the company’s $200 million Series B financing in August 2023.
Genesis Therapeutics Partners with NVIDIA to Advance AI-Driven Drug Discovery
Genesis Therapeutics, an AI-focused
Read More
Q/A: Medidata VP Talks Overcoming Financial Barriers to Diversity in Clinical Trials
Achieving diversity in clinical trials is crucial for developing effective and safe treatments for all populations. Yet, financial barriers often exclude underrepresented groups from participating, hindering progress towards health equity. This disparity raises critical questions about the accessibility and inclusivity of medical research.
In this insightful Q&A, Meghan Harrington, VP of Clinical Trial Financial Management at Medidata, a Dassault Systèmes brand, sheds light on the
Read More
Medable Unveils Generative AI to Accelerate Clinical Trial Startup
What You Should Know:
- Medable Inc., a leader in clinical development technology, has announced Medable AI, a suite of generative AI capabilities designed to revolutionize the clinical trial startup process. Medable AI empowers sponsors and clinical research organizations (CROs) to build digital and decentralized trials faster, with greater efficiency and control.
- The launch of Medable AI is part of a broader AI strategy for Medable, with plans to expand AI capabilities across its
Read More
Oxford Cannabinoid Technologies Achieves “Proof of Concept” for AI-Powered Drug Discovery
What You Should Know:
- Oxford Cannabinoid Technologies (OCT) has announced a significant milestone in its drug discovery program: the successful "proof of concept" of its AI-enabled drug discovery asset.
- Developed in collaboration with New York-based tech consultancy Hypatia AI, this cutting-edge tool promises to accelerate OCT's research and development of non-addictive pain medications.
Accelerating Drug Discovery with AI
Hypatia AI's technology acts as an "endlessly
Read More
American Brain Foundation Launches $10M Neuroinflammation Research Initiative
What You Should Know:
- The American Brain Foundation has launched a $10 million cross-disciplinary research initiative that transcends traditional research and philanthropy boundaries by bringing together nonprofit organizations, pharmaceutical and biotech investors, philanthropists, and researchers.
- The initiative will provide funding for research by top neuroscientists to investigate the role of neuroinflammation in a wide range of brain diseases, both neurologic and psychiatric,
Read More
Japan’s National Cancer Center Selects Paradigm for Nationwide Clinical Trial Network
What You Should Know:
- A new cancer treatment and research era is dawning in Japan with the launch of LC-SCRUM-CD (Lung Cancer Genome Screening Project for Individualized Medicine - Clinical Development).
- The nationwide clinical trial network is a collaborative effort between the National Cancer Center (NCC), Precision Medicine Asia Co., Ltd. (PREMIA), and Paradigm Health Inc. (Paradigm).
Building on LC-SCRUM-Asia's Foundation
LC-SCRUM-CD expands upon the existing
Read More
